1. Is radiotherapy still necessary for diffuse large B-cell lymphoma therapy?
- Author
-
Patrizia Mondello, Salvatore Cuzzocrea, Michael Mian, Carmela Aloisi, and Vincenzo Pitini
- Subjects
Pathology ,medicine.medical_specialty ,medicine.medical_treatment ,BRITISH-COLUMBIA ,Aggressive lymphoma ,Antibodies, Monoclonal, Murine-Derived ,immune system diseases ,hemic and lymphatic diseases ,MALIGNANT-LYMPHOMA ,RADIATION-THERAPY ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,ONCOLOGY-GROUP ,Radiology, Nuclear Medicine and imaging ,Cyclophosphamide ,neoplasms ,ELDERLY-PATIENTS ,PROGNOSTIC INDEX ,CHOP PLUS RADIOTHERAPY ,biology ,medicine.diagnostic_test ,business.industry ,LOCALIZED AGGRESSIVE LYMPHOMA ,NON-HODGKINS-LYMPHOMAS ,Hematology ,General Medicine ,medicine.disease ,Lymphoma ,Radiation therapy ,YOUNG-PATIENTS ,Oncology ,Doxorubicin ,Vincristine ,Positron emission tomography ,Positron-Emission Tomography ,Monoclonal ,biology.protein ,Prednisone ,Lymphoma, Large B-Cell, Diffuse ,Antibody ,Rituximab ,business ,Diffuse large B-cell lymphoma - Abstract
To the Editor, Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma subtype, accounting for approximately 30% of new cases of non-Hodgkin's lymphoma (NHL) [1]. Despite its a...
- Published
- 2015